Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

S. A. Long, M. Rieck, S. Sanda, J. B. Bollyky, P. L. Samuels, R. Goland, A. Ahmann, A. Rabinovitch, S. Aggarwal, D. Phippard, L. A. Turka, M. R. Ehlers, P. J. Bianchine, K. D. Boyle, S. A. Adah, J. A. Bluestone, J. H. Buckner, C. J. Greenbaum

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)S91
JournalDiabetes Technology and Therapeutics
Issue numberSUPPL.1
StatePublished - Jun 1 2013

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this